Ginkgo Bioworks Holdings, Inc. DNA

Ginkgo Bioworks Holdings, Inc., anteriormente Spinning Eagle Acquisition Corp, se dedica a construir una plataforma para programar células. La plataforma de la empresa se utiliza para programar células en nombre de sus clientes. Sus programas celulares están diseñados para permitir la producción biológica de productos como terapéuticos, ingredientes alimentarios clave y productos químicos derivados del petróleo. La plataforma de la empresa se utiliza para diseñar, escribir y depurar código de ácido desoxirribonucleico (ADN) en organismos modificados para ejecutar programas para sus clientes. Su plataforma es utilizada por los clientes para procesos de fabricación o para desarrollar nuevos productos a través de la biología. La base de su plataforma incluye dos activos que ejecutan una variedad de programas celulares para los clientes según sus especificaciones: Foundry y Codebase. La empresa presta servicios a industrias como la química, la agricultura, la alimentación, los productos de consumo y la farmacéutica.

DNA hizo una agrupación de acciones (split inverso) de 1:40 el 20 de agosto de 2024: cada 40 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 24 sept

  AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors

  Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.

  

• Zacks Investment Research 23 sept

  Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know

  Ginkgo Bioworks (DNA) declined 8.43% in trading, significantly underperforming the broader market. The stock has gained 24.27% over the past month but faces headwinds with expected earnings of -$0.58 per share and projected revenue decline of 47.22% year-over-year. The company holds a Zacks Rank #3 (Hold) rating with stagnant EPS projections over the past 30 days.

  

• Zacks Investment Research 16 sept

  Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts

  Ginkgo Bioworks (DNA) closed at $7.06, up 1% while the broader market declined. The stock has gained 7.04% over the past month, outperforming the Medical sector. However, analysts expect significant revenue decline of 47.22% in the upcoming quarter and 51.69% for the full year, with continued losses. The company holds a Zacks Rank of #3 (Hold), and its industry ranks in the bottom 33% of sectors.

  

• The Motley Fool 28 jun

  Palantir's Bold Biosecurity Opportunity Could Be Bigger Than Investors Think

  Palantir and Ginkgo Bioworks are positioned on opposite sides of an emerging biosecurity debate. Palantir represents the intelligence layer for threat identification, while Ginkgo represents the biological infrastructure layer for faster biological responses. The article explores whether future value will come from identifying threats first or building faster biological response capabilities.